Search

Financial Statements 2024

Media

https://www.gsk.com/media/11854/financial-statements-2024.pdf

First published: 27 February 2025

Responsible Business Performance Report 2024

Media

https://www.gsk.com/media/11863/responsible-business-performance-report-2024.pdf

First published: 27 February 2025

GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD

Media

GlaxoSmithKline plc (LSE:GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-at-ats-2014-from-study-evaluating-efficacy-and-safety-of-incruse-ellipta-added-to-advair-diskus-in-patients-with-copd/

First published: 19 May 2014

GSK publishes historical quarterly restated financial information

Media

GSK will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area

https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-historical-quarterly-restated-financial-information/

First published: 21 March 2014

GSK to support training of frontline health workers across Ghana, Kenya and Nigeria

Media

GSK is to support the training of more than 9,000 health workers in Ghana, Kenya and Nigeria over the next three years.

https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-training-of-frontline-health-workers-across-ghana-kenya-and-nigeria/

First published: 22 May 2015

GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer

Media

GSK announced that, it has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India.

https://www.gsk.com/en-gb/media/press-releases/gsk-increases-stake-in-indian-pharmaceuticals-subsidiary-to-75-per-cent-after-open-offer/

First published: 10 March 2014

Serious Fraud Office Investigation

Media

GSK has today been informed by UK's SFO that it has opened a formal criminal investigation into the Group’s commercial practices.

https://www.gsk.com/en-gb/media/press-releases/serious-fraud-office-investigation/

First published: 27 May 2014

Sir Jonathan Symonds CBE

Company

Jon was appointed to the Board as Chair on 1 September 2019 with extensive international financial, life sciences and governance experience.

https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/sir-jonathan-symonds/

First published: 27 February 2025

GSK announces regulatory submissions for mepolizumab in severe eosinophilic asthma

Media

GSK announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for patients with severe eosinophilic asthma

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-mepolizumab-in-severe-eosinophilic-asthma/

First published: 05 November 2014

Results announcement for fourth quarter 2013

Media

GSK announces core EPS of 112.2p and dividend of 78p.

https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-fourth-quarter-2013/

First published: 05 February 2014